Troubled US biotech Aeterna Zentaris has called in outside help to assist with a strategic review after a disastrous few months that saw the company axe its CEO, David Dodd.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh